Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Doumas

Showing results (41-50 of 380) with videos related to

Pageof 38
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|April 29, 2014
Renal nerve ablation for resistant hypertension: the dust has not yet settledMichael Doumas, Antonios Lazaridis, Vasilios Papademetriou
Journal of Clinical Hypertension (Greenwich, Conn.)|August 4, 2015
Exaggerated Blood Pressure Response to Exercise: Will It Ever Be Ready for Prime Time?Michael Doumas, Charles Faselis, Peter Kokkinos
JAMA Surgery|November 18, 2020
The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
International Journal of Cardiology|February 24, 2021
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 26, 2021
Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart FailureDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Hypertension (Dallas, Tex. : 1979)|June 18, 2019
Renal Sympathetic Denervation in Isolated Systolic HypertensionMichael Doumas, Vasilios Papademetriou, Costas Tsioufis
Diabetes & Metabolic Syndrome|April 20, 2020
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|June 1, 2022
Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The New England Journal of Medicine|February 16, 2022
Tirzepatide versus Semaglutide Once Weekly in Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
European Journal of Heart Failure|January 6, 2022
Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'Michael Doumas, Dimitrios Patoulias, Christodoulos Papadopoulos
Pageof 38

Showing results (41-50 of 380) with videos related to

Sort By:
Pageof 38
Journal of Clinical Hypertension (Greenwich, Conn.)|April 29, 2014
Renal nerve ablation for resistant hypertension: the dust has not yet settledMichael Doumas, Antonios Lazaridis, Vasilios Papademetriou
Journal of Clinical Hypertension (Greenwich, Conn.)|August 4, 2015
Exaggerated Blood Pressure Response to Exercise: Will It Ever Be Ready for Prime Time?Michael Doumas, Charles Faselis, Peter Kokkinos
JAMA Surgery|November 18, 2020
The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
International Journal of Cardiology|February 24, 2021
Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 26, 2021
Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart FailureDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
Hypertension (Dallas, Tex. : 1979)|June 18, 2019
Renal Sympathetic Denervation in Isolated Systolic HypertensionMichael Doumas, Vasilios Papademetriou, Costas Tsioufis
Diabetes & Metabolic Syndrome|April 20, 2020
Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The American Journal of Cardiology|June 1, 2022
Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
The New England Journal of Medicine|February 16, 2022
Tirzepatide versus Semaglutide Once Weekly in Type 2 DiabetesDimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas
European Journal of Heart Failure|January 6, 2022
Epicardial adipose tissue: does it mediate the cardio-protective effects of sodium-glucose co-transporter 2 inhibitors in patients with heart failure? Letter regarding the article 'Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure'Michael Doumas, Dimitrios Patoulias, Christodoulos Papadopoulos
Pageof 38